QbD and RTRT - New Question and Answers published by EMA
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
In June 2013, the European Medicines Agency (EMA) added, among others, three new questions regarding cooperation between assessors and inspectors when processing Quality by Design (QbD) applications involving RTRT (Real Time Release Testing).
In cases of RTRT applications, the assessor should contact the relevant supervisory authority at the earliest opportunity to discuss the potential implications and clarify whether or not a GMP inspection is needed.
The level of cooperation depends on the complexity. A discussion between assessor and inspector is important to achieve a common understanding of the applicant's proposal and its potential impact on the marketing authorisation dossier and on-site situation. If a manufacturer uses complex technology (such as NIR or Raman spectroscopy) for RTRT for the first time, a product-specific inspection may be requested.
A further question addresses the data generated during parallel testing. Results of parallel testing should normally be included in the MA or variation submission, but can also be submitted later.
For more detailed information please also see the EMA "Quality of medicines questions and answers: Part 2"
Related GMP News
22.04.2026No Validation, No Controls, and No Suitable Rooms and Equipment - Extensive Warning Letter
25.03.2026FDA Warning Letter highlights once again: Weaknesses in the CAPA Process remain a key GMP Issue
18.03.2026FDA Issues Draft Guidance on Responding to Form 483 Observations
28.01.2026What is the Procedure for GMP Inspections (EU GMP inspections and FDA Inspections)?
21.01.2026FDA Warning Letter highlights critical Failures in Supplier and Quality Oversight
19.01.2026GMP Auditor Association Developments September through December 2025